Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Garadacimab in hereditary angioedema due to normal C1INH with F12/PLG mutations.

The Journal of allergy and clinical immunology - 1 Dec 2025

Cohn Danny M, Reshef Avner, Staubach Petra, Lumry William R, Feuersenger Henrike, Jacobs Iris, Pragst Ingo, Zuraw Bruce, Bork Konrad

Abstract excerpt

BACKGROUND: Hereditary angioedema (HAE) with normal C1 inhibitor (HAE-nC1INH), including HAE arising from F12 (HAE-FXII) or PLG (HAE-PLG) mutations, has a high unmet therapeutic need. OBJECTIVE: Our aim was to explore long-term prophylaxis with monthly subcutaneous garadacimab (anti-activated factor XII mAb) in patients with HAE-FXII or HAE-PLG. METHODS: Efficacy and safety were evaluated for HAE-FXII or HAE-PLG...

Topics

Join the communities discussing this publication.

Adolescent
Aged
Angioedemas, Hereditary
Antibodies, Monoclonal, Humanized
Complement C1 Inhibitor Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40876763
DOI: 10.1016/j.jaci.2025.08.005

Genes

PLG
AR
F12

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Garadacimab in hereditary angioedema due to normal C1INH with F12/PLG mutations.PMID 40876763Read ↗

Hereditary angioedema with normal C1 inhibitor: clinical characteristics and treatment response with plasma-derived human C1 inhibitor concentrate (Berinert®) in a French cohort.Semantic proximity Read ↗

The future of therapeutic options for hereditary angioedema.Semantic proximity Read ↗

Hereditary Angioedema with Normal C1 Inhibitor: Update on Evaluation and Treatment.Semantic proximity Read ↗

Hereditary AngioedemaSemantic proximity Read ↗

Effectiveness of lanadelumab in patients with hereditary angioedema with normal C1 inhibitor and FXII mutation.Semantic proximity Read ↗

Hereditary and acquired angioedema.Semantic proximity Read ↗

Real-World Evidence on the Management of Hereditary Angioedema With Normal C1 Inhibitor.Semantic proximity Read ↗

Overview of hereditary angioedema caused by C1-inhibitor deficiency: assessment and clinical management.Semantic proximity Read ↗

Diagnosis and treatment of hereditary angioedema.Semantic proximity Read ↗

Definition and classification of hereditary angioedema.Semantic proximity Read ↗

Type II hereditary angioedema with an apparently de novo SERPING1 mutation in China: A case report and family screening.Semantic proximity Read ↗

Clinical features of genetically characterized types of hereditary angioedema with normal C1 inhibitor: a systematic review of qualitative evidence.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.